The executive team of Alumis will lead the combined entity. Credit: Asian Isolated/Shutterstock. Alumis and Acelyrin have ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Relmada has acquired complete ownership rights to Sepranolone, developed for Tourette syndrome (TS) from Asarina Pharma.

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

In addition to the UK investment controversy, AstraZeneca is also dealing with legal challenges in China. The company ...

With Dry January firmly behind us, many adults are prompted to reassess their relationship with alcohol. Alcohol Change, the UK charity behind the popular Dry January initiative, found that 30% of men ...

The USPTO has granted a patent to Vistagen’s non-opioid oral product candidate AV-101 for neuropathic pain treatment.

The US Food and Drug Administration (FDA) rejected three prior regulatory applications before granting approval.

The last few days have been a rollercoaster for the pharmaceutical industry. Mexico and Canada were bracing themselves for ...

Experts at the 2025 Clinical Trial Supply Europe conference will explore supply chain challenges and the impact of AI on ...